Lastly, our findings implicate oncogenic c-terminal mutations of CCND1 in the pathogenesis of a subset of human cancers and provide a key resource to guide future preclinical and clinical investigations, especially with regards to the use of palbociclib or similar CDK4/6 specific inhibitors in a subset of endometrial cancers. The gene discussed is CDK4; the disease is cancer.